Overactive bladder

Axonics® to Participate in BofA Securities 2022 Healthcare Conference

Retrieved on: 
Tuesday, April 26, 2022
Biotechnology, Medical Devices, Other Health, Health, Medical Supplies, Deloitte Technology Fast 500, Conference, SNM, Overactive bladder, Bank of America, Financial Times, Fecal incontinence, Nasdaq, Urinary incontinence, Woman, Patient, SUI, Dietary supplement, Axon Enterprise

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022.
  • A live webcast and archived replay of the presentation will be accessible on the Axonics investor relations website .
  • Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction.
  • 1 on the 2021 Deloitte Technology Fast 500 and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.

Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA® in Dry and Wet Overactive Bladder Populations

Retrieved on: 
Tuesday, April 19, 2022
Health, Pharmaceutical, Overactive bladder, Urinary urgency, Urination, Woman, Population, Urinary tract infection, Drug, Patient, Sore throat, LinkedIn, Vibegron, Nocturia, Allergy, Urinary incontinence, Journal, FDA, Upper respiratory tract infection, Diarrhea, Breast milk, Adult, Paced Auditory Serial Addition Test, Hypertension, Incidence, Digoxin, The Journal of Urology, Canadian International Council, Liver, Man, Senior, Nausea, Vitamin, International Journal of Clinical Practice, Medicine, Twitter, MD, Urinary retention, Safety, OAB, Kidney, Nasal congestion, Common, Gesellschaft mit beschränkter Haftung, Urine, Headache, NYSE, Â, Science, Pharmaceutical industry, Copper, Dietary supplement, Fine chemical, Urology

The peer-reviewed paper is entitled, Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial.

Key Points: 
  • The peer-reviewed paper is entitled, Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial.
  • OAB is characterized by urgency and frequency with (OAB wet) or without (OAB dry) urge urinary incontinence (UUI).
  • The post-hoc analysis was developed to compare efficacy of vibegron vs. placebo in OAB wet and dry populations.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo, GEMTESA, and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System

Retrieved on: 
Tuesday, April 19, 2022
Biotechnology, Health, Medical Devices, Deloitte Technology Fast 500, Overactive bladder, CEO, Financial Times, Woman, Longevity, F15, SUI, DTC, Urinary incontinence, Patient, Fecal incontinence, Nasdaq, SNM, Physician, FDA, Incontinence, Pharmaceutical industry, Axon Enterprise

The newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system received FDA approval in March.

Key Points: 
  • The newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system received FDA approval in March.
  • Clinical outcomes with the Axonics rechargeable SNM system have exceeded our expectations and we anticipate similar results with the Axonics F15.
  • Raymond W. Cohen, CEO of Axonics, said, Physician response to the Axonics F15 has been overwhelmingly positive.
  • Axonics sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy.

Axonics® to Report First Quarter 2022 Financial Results on May 5

Retrieved on: 
Thursday, April 14, 2022
General Health, Health, Medical Supplies, Medical Devices, Deloitte Technology Fast 500, SNM, Overactive bladder, Event, Interest, Financial Times, Fecal incontinence, Nasdaq, Woman, Urinary incontinence, Patient, Webcast, SUI, Video game, Dietary supplement, Axon Enterprise

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report first quarter 2022 financial results after the market closes on Thursday, May 5, 2022.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report first quarter 2022 financial results after the market closes on Thursday, May 5, 2022.
  • In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time.
  • A live webcast of the conference call may be accessed by visiting the Events & Presentations section of the Axonics investor relations website.
  • 1 on the 2021 Deloitte Technology Fast 500 and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.

Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual Meeting

Retrieved on: 
Wednesday, April 13, 2022
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Patient, Vitamin, Breast milk, Overactive bladder, Kidney, Urinary urgency, Urination, Medicine, Public health, Woman, Cystoscopy, I, Urinary tract infection, Twitter, Adult, Nasal congestion, Incidence, Neurogenic bladder dysfunction, Urinary retention, Sore throat, Burden, Digoxin, Kopp, LinkedIn, Injection, Vats, Urine, Nocturia, Allergy, Sex, Female, Liver, Urinary incontinence, Man, Headache, NYSE, Safety, FDA, OAB, Diarrhea, Nausea, Upper respiratory tract infection, Pharmaceutical industry, Medical imaging, Dietary supplement, Urology, Sexton

URO-902 has the potential to be the first gene therapy for patients with OAB.

Key Points: 
  • URO-902 has the potential to be the first gene therapy for patients with OAB.
  • If approved, this innovative treatment has the potential to address an unmet need for patients who have failed oral pharmacologic therapies.
  • Secondary endpoints were changes from EMPOWUR baseline at week 52 in average daily micturitions, UUI, urgency, and total urinary incontinence.
  • Sumitovant is a global biopharmaceutical company leveraging data-driven insights to rapidly accelerate development of new potential therapies for unmet patient conditions.

Avation Medical Announces Appointment of Chief Marketing Officer to Executive Leadership Team

Retrieved on: 
Wednesday, April 13, 2022
DME, University, Paul the Apostle, CEO, Commercial Operating System (COS), Marketing, IPO, MBA, VP, NASDAQ, Medicine, St. Jude Medical, Patient, Growth, Olympus, Lymphedema, SVP, Company, Urinary incontinence, History, Avation, Overactive bladder, TCMD, OAB, FDA, Pharmaceutical industry, COLUMBUS

COLUMBUS, Ohio, April 13, 2022 /PRNewswire/ -- Avation Medical, an innovative neuromodulation and digital health company pioneering a wearable system to treat the symptoms of overactive bladder (OAB) and urge urinary incontinence (UUI), today announced the appointment of Darren Wennen as its Chief Marketing Officer.  He will be responsible for all aspects of marketing, sales operations and customer care as the Company prepares to bring its novel wearable therapy and digital support system to market.  

Key Points: 
  • Avation Medical appoints Darren Wennen, a medical industry veteran, as Chief Marketing Officer in anticipation of commercialization of its wearable neuromodulation system to treat OAB and UUI.
  • COLUMBUS, Ohio, April 13, 2022 /PRNewswire/ --Avation Medical, an innovative neuromodulation and digital health company pioneering a wearable system to treat the symptoms of overactive bladder (OAB) and urge urinary incontinence (UUI), today announced the appointment of Darren Wennen as its Chief Marketing Officer.
  • "I am thrilled to welcome Darren to Avation Medical.
  • Mr. Wennen brings to Avation Medical a demonstrated history of successful product launches and sales growth.

Specialty Networks Partners with Datavant to Bring Real-world Specialty Data to Life Sciences Research through its SoNaR Registry

Retrieved on: 
Tuesday, April 12, 2022
Family, Inflammatory bowel disease, Friction, Psoriasis, Rheumatism, Sonar, Rheumatology, Research, Center, Organization, GLOBE, Osteoarthritis, Patient, Gastroenterology, SAN, Time-invariant system, Technology, Privacy, Center of excellence, Health, List of life sciences, Solution, Huntingdon, Neoplasm, Eurosport 1, Urology, Overactive bladder, Hope, James Whale Fund for Kidney Cancer, Physician, Population Health Management, Industry, Disease, Partnership, Prostate, Medicine, Medical imaging

Leveraging Datavants ecosystem of more than 500 real-world data partners, Specialty Networks will link other data sources like claims, labs, imaging, mortality events, and social determinants to create a complete longitudinal patient journey.

Key Points: 
  • Leveraging Datavants ecosystem of more than 500 real-world data partners, Specialty Networks will link other data sources like claims, labs, imaging, mortality events, and social determinants to create a complete longitudinal patient journey.
  • SoNaR Specialty Networks Registry represents the family of highly curated specialty registries in urology, gastroenterology, and rheumatology for various tumors and disease states.
  • Specialty Networks is establishing a gold standard in urology for real-world evidence research with its SoNaR registry and technology stack that integrates a large proportion of independent community physician practices across the country.
  • Specialty Networks (SN) is an integrated, multi-specialty organization with GPOs, Life Sciences, and Research solutions in urology, gastroenterology, and rheumatology.

BlueWind Medical Ltd. Appoints Charles F. Cargile as Chief Financial Officer

Retrieved on: 
Tuesday, April 12, 2022
Urine, Company, IDE, Journal of Managed Care & Specialty Pharmacy, Urinary incontinence, American Urological Association, Marketing, United Kingdom, Chuck, Business, Board, Oklahoma State University–Stillwater, European Urology, PARK, OASIS, CFO, Mental health, Effectiveness, Overactive bladder, Kopp, Audit committee, Woman, CEO, Food, Newport Corporation, Director, OAB, Financial compensation, Regulation of tobacco by the U.S. Food and Drug Administration, Commercial software, Housing, Communities and Local Government Committee, FDA, University, Patient, Committee, Accounting, Management, Silviculture, Mirabegron, Man

PARK CITY, Utah, and HERZLIYA, Israel, April 12, 2022 /PRNewswire/ -- BlueWind Medical, Ltd., developer of the innovative RENOVA iStim™ implantable tibial neuromodulation (iTNM) device for treatment of Overactive Bladder, today announced the addition of Charles F. ("Chuck") Cargile to its leadership team as Chief Financial Officer.

Key Points: 
  • PARK CITY, Utah, and HERZLIYA, Israel, April 12, 2022 /PRNewswire/ -- BlueWind Medical, Ltd., developer of the innovative RENOVA iStim implantable tibial neuromodulation (iTNM) device for treatment of Overactive Bladder, today announced the addition of Charles F. ("Chuck") Cargile to its leadership team as Chief Financial Officer.
  • He will be a strong partner and an invaluable addition to the team," said Dan Lemaitre, Chairman and CEO of BlueWind Medical.
  • "With the potential for FDA marketing clearance in 2023, the addition of Chuck further prepares BlueWind Medical for commercialization and our next phase of corporate growth."
  • Mr. Cargile has more than 25 years of public company executive experience including 16 years as Chief Financial Officer of Newport Corporation from 2000 to 2016; 4 years as Chief Executive Officer and Chairman of the Board of Sunworks, Inc. from 2017 to 2021; and Chief Financial Officer of The Tattooed Chef from 2020 to 2021.

Urovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice President and Chief Medical Officer

Retrieved on: 
Monday, April 4, 2022
Health, Pharmaceutical, LinkedIn, Headache, Paced Auditory Serial Addition Test, Upper respiratory tract infection, Nasal congestion, United Kingdom, Diarrhea, University of the Witwatersrand, CMO, NYSE, Adult, Overactive bladder, Digoxin, Kidney, Allergy, Urinary incontinence, Urinary retention, Urinary tract infection, Medicine, Health, Pediatrics, Man, Nausea, CEO, Senior, Breast milk, Science, Lead, Allergan, Inc., Industry, Pfizer, Vitamin, Sore throat, Twitter, OAB, Drug, Liver, FDA, University, Patient, Management, Pharmaceutical industry, Fine chemical, Dietary supplement, Urology, VideoRay UROVs, Health, Pharmaceutical

Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced Sef Kurstjens, M.D., PhD., has been appointed Executive Vice President and Chief Medical Officer (CMO).

Key Points: 
  • Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced Sef Kurstjens, M.D., PhD., has been appointed Executive Vice President and Chief Medical Officer (CMO).
  • I am delighted to welcome Sef Kurstjens to the executive leadership team to lead our clinical and medical affairs activities.
  • His appointment reflects his deep commitment to Urovant and improving the lives of people with urological conditions, said James Robinson, president and CEO of Urovant Sciences.
  • Dr. Kurstjens appointment comes as we work to expand commercial access to GEMTESA and advance our product pipeline.

Axonics® Launches Direct to Consumer Television Advertising Campaign

Retrieved on: 
Monday, April 4, 2022
Other Health, Managed Care, General Health, Consumer, Medical Devices, Marketing, Women, Advertising, Biotechnology, Communications, Medical Supplies, Health, Private Securities Litigation Reform Act, Population, List, Television, SNM, Nursing, Urinary incontinence, Incontinence, Woman, U.S. Securities and Exchange Commission, Science and technology in Asia, SUI, Deloitte Technology Fast 500, Doctor of Philosophy, Nasdaq, Solution, YouTube, Awareness, Telecommunication, Overactive bladder, Patient, Security (finance), Fecal incontinence, Pharmaceutical industry, Axon Enterprise, Facebook

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the launch of its direct to consumer television advertising campaign.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the launch of its direct to consumer television advertising campaign.
  • The women speak authentically about the challenges of living with incontinence and how Axonics has provided them life-changing symptom relief.
  • The Find Real Relief campaign will also include targeted advertising on YouTube, Facebook, digital audio, and various websites.
  • We are excited to launch this television advertising campaign and we are confident that it will continue to drive SNM market expansion and advance Axonics on its path to market leadership.